The debate crystallizes a genuine tension between a strong structural bull thesis and an equally strong tactical bear thesis, and the most honest read is that neither side has decisively won. On the bull side, the valuation case is hard to dismiss: a sole-source defense prime with F-35, THAAD, PAC-3, and Trident D5 franchise positions, a 2.64% dividend yield, beta of essentially zero, and a forward P/E near 15.86x with double-digit EPS growth is not expensive in absolute terms. The Q2'26 fundamentals reinforce this — second-highest revenue quarter ever at $20.06B (+11.3% YoY), operating margin recovered to 12.4% from the anomalous 4.1% trough, and $3.6B of net debt reduction year-over-year. The contract flow (PrSM, PAC-3/THAAD framework, allied demand) does build multi-year revenue visibility even if its short-term stock impact has been muted. On the bear side, the single most damaging observation is that the bull's "avalanche of catalysts" has produced essentially zero net price movement — $1.2B in new contracts and a 7-year framework deal have not broken the lower-high/lower-low pattern that has been in place since August. The market is telling us something: incremental contract wins at this scale don't meaningfully move a $77B revenue base, and other concerns (fixed-price program risk, F-35 concentration of 25-30% of revenue, long-end yields at 2004 highs compressing long-duration multiples) are weighing on the multiple more than the catalysts are lifting it. The technical structure is unambiguously damaged — price below all major moving averages, MACD negative and not crossed, RSI at 37.5 with no confirmed bullish divergence, VWMA above price, and lower highs and lower lows intact. The bear's probability-weighting critique of the bull's asymmetry math is also valid: the market has rejected the $638 consensus target for seven straight months, so the "22% upside to consensus" framing deserves skepticism. The synthesis: this is a quality franchise trading at a reasonable valuation, in a confirmed intermediate-term downtrend, with real but bounded upside catalysts that aren't currently being rewarded. That combination does not warrant aggressive accumulation, but it also doesn't warrant selling a low-beta, dividend-paying, sole-source franchise into a 21% drawdown. The right posture is to hold the position, decline to add aggressively into the downtrend, and wait for technical repair (price above the 10 EMA, MACD bullish cross, RSI reclaiming 50) before increasing exposure — and to be willing to reassess or trim if the $500 psychological level gives way on volume.

POSITION STRATEGY: MAINTAIN current LMT position; do not add aggressively at $519. The confirmed downtrend (price below 10/50/200 SMA, MACD negative, lower highs/lows intact) means fighting the tape into resistance at the 50 SMA ($555) and VWMA ($530) carries unfavorable risk/reward.

ACCUMULATION TRIGGERS: DEFINE accumulation triggers before adding: (a) price reclaim of the 10 EMA at ~$528 with a daily close, AND (b) MACD bullish crossover with histogram turning positive, AND (c) RSI sustained above 50. All three conditions should be met before scaling exposure higher.

RISK TRIGGERS: DEFINE risk triggers for trim/reassess: a close below $500 on rising volume would invalidate the consolidation thesis and likely trigger a move toward $470-475; a close below $475 would confirm a broader breakdown and warrant meaningful position reduction.

POSITION SIZING: Keep current allocation at or below benchmark weight; do not overweight until technical structure repairs. The 2.64% dividend yield and low beta justify maintaining the position, but the bear is right that the asymmetric setup the bull describes is overstated until the chart confirms.

CATALYST CALENDAR: Monitor Q3 2026 earnings (mid-October) for program charge disclosure, FY27 NDAA markup progress, and any F-35 follow-on development cost updates. Re-evaluate the recommendation at Q3 print — a clean quarter with no program charges and constructive guidance would be a meaningful positive catalyst that could break the downtrend; another Q2'25-style charge would confirm the bear's structural fixed-price risk concern.

PEER REALLOCATION: If capital needs to be reallocated, prefer higher-quality defense names with cleaner fixed-price exposure (NOC, RTX) over adding to LMT at current levels; the bear's peer comparison argument (LMT is the cheapest prime for a reason) is worth honoring tactically.

UPSIDE TARGETS: Monitor on recovery: $555 (50 SMA — first meaningful reclaim), $584 (prior breakout level from late summer), $638 (consensus PT), $798 (UBS PT, which assumes catalysts fully reprice). Use these as staged trim points if the position is increased and the stock recovers.

The investment plan crystallizes a genuine tension: LMT's structural bull case (sole-source F-35/THAAD/PAC-3/Trident D5 franchises, 2.64% yield, ~zero beta, forward P/E ~15.86x with double-digit EPS growth, and Q2'26's $20.06B revenue (+11.3% YoY) with operating margin recovery to 12.4%) is compelling, but the tactical bear case is equally weighty — $1.2B in new contracts plus a 7-year framework deal have produced zero net price movement, the lower-high/lower-low pattern since August remains intact, and the technicals are unambiguously damaged (price below 10/50/200 SMA, MACD negative, RSI at 37.5, VWMA overhead at $530). The bear's critique that the bull's asymmetry math is overstated is valid: the market has rejected the $638 consensus target for seven consecutive months. With price near $519 sitting below all major moving averages and resistance at the 50 SMA ($555) and VWMA ($530), fighting the tape carries unfavorable risk/reward, yet selling a low-beta, dividend-paying sole-source franchise into a 21% drawdown is equally imprudent. The right posture is to hold, await technical repair (price >10 EMA at ~$528, MACD bullish cross, RSI >50) before scaling exposure, and reassess at Q3'26 earnings (mid-October) where a clean print could break the downtrend or another program charge could confirm fixed-price risk.

Stop loss: $500.00

Sizing: Maintain current allocation at or below benchmark weight; do not overweight until technical structure repairs (price above 10 EMA ~$528 with bullish MACD cross and RSI sustained >50).